GlassScriptPhysician profile
Pascale Lane
NPI 1831136043
$1,468.29
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,288 · 2021: $23.35 · 2022: $123 · 2023: $33.68.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $33.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $33.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $803.81 | 2019 | |
| Travere Therapeutics, INC. | $268.24 | 2019-2023 | |
| Veloxis Pharmaceuticals, INC. | $124.39 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $118.07 | 2019 | |
| Alexion Pharmaceuticals, INC. | $116.26 | 2019 | |
| Azurity Pharmaceuticals, INC. | $23.35 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.17 | 2019 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pascale Lane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.